Catalyst Pharmaceuticals (CPRX) Expected to Announce Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX) is projected to announce its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Catalyst Pharmaceuticals to post earnings of $0.42 per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX opened at $24.11 on Tuesday. The business’s 50-day simple moving average is $23.83 and its 200-day simple moving average is $22.11. Catalyst Pharmaceuticals has a 52 week low of $19.05 and a 52 week high of $26.58. The firm has a market cap of $2.96 billion, a price-to-earnings ratio of 14.02, a P/E/G ratio of 0.81 and a beta of 0.74.

Analysts Set New Price Targets

CPRX has been the topic of several analyst reports. Weiss Ratings reiterated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Monday, December 29th. Citigroup upped their price objective on shares of Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, November 16th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $33.20.

Insiders Place Their Bets

In other news, insider Carmen Jeffrey Del sold 10,983 shares of the company’s stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $23.33, for a total transaction of $256,233.39. Following the completion of the transaction, the insider owned 3,962 shares of the company’s stock, valued at approximately $92,433.46. This represents a 73.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Molly Harper sold 26,746 shares of the stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $23.25, for a total transaction of $621,844.50. Following the completion of the sale, the director owned 2,360 shares of the company’s stock, valued at approximately $54,870. The trade was a 91.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 10.40% of the company’s stock.

Institutional Trading of Catalyst Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtus Advisers LLC raised its stake in shares of Catalyst Pharmaceuticals by 647.3% in the third quarter. Virtus Advisers LLC now owns 14,572 shares of the biopharmaceutical company’s stock worth $287,000 after acquiring an additional 12,622 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Catalyst Pharmaceuticals by 3,227.3% in the second quarter. Tower Research Capital LLC TRC now owns 12,444 shares of the biopharmaceutical company’s stock valued at $270,000 after purchasing an additional 12,070 shares in the last quarter. CIBC Bancorp USA Inc. bought a new position in Catalyst Pharmaceuticals in the 3rd quarter worth approximately $243,000. PharVision Advisers LLC acquired a new position in Catalyst Pharmaceuticals during the 3rd quarter worth $243,000. Finally, E Fund Management Co. Ltd. lifted its holdings in Catalyst Pharmaceuticals by 8.9% during the 2nd quarter. E Fund Management Co. Ltd. now owns 10,656 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 871 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).